Xconomy | San Diego - Business + Technology in the Exponential Economy

Navy to Test Vical Vaccine Combo

San Diego-based biotech firm Vical (NASDAQ:VICL) reports that the Naval Medical Research Center plans to conduct tests and early clinical trials of a DNA vaccine formulated with its vaccine adjuvant (Vaxfectin) with a needle-free injection system for potentially lethal dengue infections. Vical plans to manufacture the vaccine and adjuvant under a $1.3 million contract, and the study is expected to take place at Walter Reed Army Institute of Research.

Ryan McBride is Xconomy's correspondent. You can reach him at rmcbride@xconomy.com, or follow him on Twitter at http://twitter.com/Ryan_McBride.

Comments | Reprints | Share: